AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Veery Capital LLC

Veery Capital LLC raised its position in AstraZeneca PLC (NASDAQ:AZN) by 4.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,503 shares of the company’s stock after buying an additional 157 shares during the period. Veery Capital LLC’s holdings in AstraZeneca were worth $230,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Bank of Montreal Can grew its holdings in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after buying an additional 1,605,758 shares in the last quarter. Franklin Resources Inc. boosted its position in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after acquiring an additional 1,522,715 shares during the last quarter. Farallon Capital Management LLC grew its stake in AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after acquiring an additional 950,000 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in AstraZeneca in the 3rd quarter valued at about $72,437,000. Finally, Fisher Asset Management LLC lifted its stake in AstraZeneca by 5.3% in the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after purchasing an additional 524,175 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

AZN opened at $66.60 on Friday. The stock’s 50-day moving average price is $66.11 and its 200 day moving average price is $74.49. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The firm has a market cap of $206.50 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 1.05 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.87 earnings per share. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.